

SPECT and PET imaging, however, require different instrumentation: scintillation cameras used for SPECT imaging are generally regarded as too insensitive for effective PET imaging, while PET scanners cannot effectively image single photon emitting tracers used for SPECT. This newly developed system attempts to bridge this gap by using two uncollimated, tiltable scintillation cameras in time coincidence, rotated about the target to acquire PET image data. Tilting the cameras in the prescribed manner allows a tradeoff between axial field-of-view and photon path length through the scintillator that maximizes 2D coincidence sensitivity compared to cameras in full opposition. The resulting system exhibits the high spatial resolution expected of a scintillation camera at 511 keV but with substantially higher coincidence sensitivity. (portfolio: Devices/Instrumentation—Diagnostics, imaging apparatus, positron emission tomography)

Enzymatic Degrading Subtraction Hybridization

J Zeng (NCI)
Serial No. 08/322,075 filed 12 Oct 94
U.S. Patent No. 5,525,471 issued 11 Jun 96

The present invention provides an alternative method for selection and identification of differentially expressed genes involved in embryonic development and in the onset or maintenance of various pathological conditions due to genetic alterations in somatic cells. This method involves the prior modification of tester cDNA which contains the sequences of interest by incorporation of nuclease resistant nucleotide analogs. Driver cDNA not containing the sequences of interest is then used to remove sequences common to driver and tester cDNA populations through hybridization and subsequent exonuclease digestion, substantially enriching for the desired sequences. This method can also be used in conjunction with the phenol-emulsion reassociation technique (PERT), which significantly accelerates the hybridization rate allowing, the cDNA molecules to be efficiently subtracted using a very small amount of DNA. This method is less expensive, more efficient, and less time-consuming than previous subtraction hybridization methods. (portfolio: Cancer—Research Reagents; Cancer—Diagnostics)

Chromatographic Method and Device for Preparing Blood Serum for Compatibility Testing

R Butz (CC)

Filed 18 Oct 95
DHHS Reference No. E-141-94/0

The present invention provides a new method for antiglobulin testing of serum from a potential blood transfusion recipient. This process and device removes warm antibodies from serum to allow for the identification of alloantibodies present in the sample. The multiple absorptions required by current methods to remove the warm antibodies from serum of a potential blood transfusion recipient is superseded by this invention. The disclosed invention will remove the majority of warm antibodies in a single one-hour absorption. This invention also eliminates the need for pretreatment of cells with expensive reagents. Use of this column and method does not remove any clinically significant alloantibodies. Therefore, transfusion history accuracy and subsequent risk to the patient is greatly reduced. (portfolio: Internal Medicine—Diagnostics, cardiology; Internal Medicine—Miscellaneous)

Dated: July 8, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-18101 Filed 7-16-96; 8:45 am]
BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Method of Treating Demyelinating Diseases With Insulin-Like Growth Factor I

AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license in the United States to practice the invention embodied in U.S. Patent Application Serial Number 60/003,055, filed on August 31, 1995, entitled "Method of Treating Demyelinating Diseases With Insulin-Like Growth Factor I", to Cephalon, Inc., having a place of business in West Chester, Pennsylvania. The patent rights in this invention have been assigned to the United States of America.

The patent application claims a method to treat diseases or disorders associated with myelin injury, such as multiple sclerosis, by administering an effective amount of insulin-like growth factor I.

The prospective exclusive license will be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 90 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use would be the use of insulin-like growth factor I to treat nervous system disorders associated with perivascular lesions, such as those occurring in multiple sclerosis.

ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Leopold J. Luberecki, Jr., J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Box 13, Rockville, MD 20852-3804. Telephone: (301) 496-7735, ext. 223; Facsimile: (301) 402-0200. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before October 15, 1996 will be considered.

Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: July 8, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-18102 Filed 7-16-96; 8:45 am]
BILLING CODE 4140-01-M

Substance Abuse and Mental Health Services Administration

Minority Fellowship Program

AGENCY: Center for Mental Health Services, Substance Abuse and Mental Health Services Administration (SAMHSA), HHS.

ACTION: Notice of planned awards for renewal clinical training grants under the Minority Fellowship Program (MFP) to the American Nurses Association (ANA) and the Council on Social Work Education (CSWE).

SUMMARY: The Substance Abuse and Mental Health Services Administration's Center for Mental Health Services (CMHS) plans to award renewal MFP grants to the ANA and the